Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginseng secondary glycosides H dripping pills in advanced non-small cell lung cancer
ChiCTR-IIR-16008747Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ginseng secondary glycosides H in non-small cell lung cancer (NSCLC) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Started May 2016; status: recruiting.
02
Drugs
ginseng secondary glycosides H
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IIR-16008747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008747.